title: NXY-059. Centaur.
abstract: Centaur and AstraZeneca are developing NXY-059, an alpha-phenyl-N-tert-butyl nitrone derivative, free radical trapping agent, for the potential therapy of reperfusion injury following stroke. Phase II clinical trials are ongoing, with phase III trials in acute stroke planned for initiation in early 2003.
authors.affiliation: UCSD Neuroscience MTF 316, 9500 Gilman Drive, La Jolla, CA 92093-0624, USA. plapchak@ucsd.edu
authors.forename: Paul A
authors.initials: PA
authors.lastname: Lapchak
mesh_terms: D000818:Animals; D001557:Benzenesulfonates; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data; D004345:Drug Industry / Q000331:legislation & jurisprudence / Q000379:methods*; D006801:Humans; D009589:Nitrogen Oxides / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D020521:Stroke / Q000188:drug therapy
chemical_list: D001557:Benzenesulfonates; D009589:Nitrogen Oxides; C120851:disufenton sodium